I am a KMD and Bio-tech Director specializing in Alzheimer’s (AD). I have treated 1,000+ patients over 5 years with zero side effects. My "Selection-Prevention" model uses $A\beta$, Tau, and NfL biomarkers for early intervention. My 2021 JAD study confirmed $A\beta$/Tau reduction via AMPK.The Problem I Help Industry SolveI solve the need for validated, safe AD interventions:Efficacy: 100% $A\beta$ response (avg 20% reduction; 22% for ApoE4/4), outperforming NCAA trajectories.RWE Power: 407-patient data with 77.6% response (CGI-I) reduces R&D risk for drugs/medical foods.Scalable Standard: Establishing an A/T/N "Dual Care" standard through an upcoming 30-subject triple-marker study.